

eTable 3. Period of treatment or initiation of treatment of patients enrolled in the studies

	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Curtis 2012	Pegaptanib, bevacizumab, ranibizumab/NR												
Lad 2014	Bevacizumab, ranibizumab/NR												
Boulanger-Scemama 2015	Ranibizumab/ PRN												
Nunes 2010	Bevacizumab/ NR												
Oishi 2011			Ranibizumab/ PRN										
Vaze 2014	Ranibizumab/ NR												
Rasmussen 2013	Ranibizumab/ PRN												
Kruger Falk 2013		Ranibizumab/ PRN											
Ramakrishnan 2020			Bevacizumab or Ranibizumab/ PRN or monthly										
McGrath 2013			Ranibizumab/ T&E										
Holz 2015			Ranibizumab/ NR										
Polat 2017					Ranibizumab/ PRN								
Kim 2017							Ranibizumab, bevacizumab/ PRN						
Subhi 2017						Ranibizumab/ PRN			Aflibercept/ PRN				
Bobykin 2014							Ranibizumab/ PRN						
Ehikeh 2018a							Bevacizumab, ranibizumab/ fixed, PRN						
Ehiken, 2018								Ranibizumab, aflibercept, bevacizumab/ PRN					
Rasmussen 2017							Ranibizumab/ PRN		Aflibercept/ PRN				
Husler 2013							Ranibizumab/ NR						
Varano 2015							NR/ NR						
Heimes 2016								Ranibizumab/ PRN					
Massamba 2015								Ranibizumab/ PRN					
Krivosic 2017								Ranibizumab or Aflibercept/PRN, T&E, bimonthly					
Westborg 2018								Ranibizumab (T&E/ Aflibercept (fixed)					
Jansen 2018								NR/NR					
Wintergerst 2018										NR/ NR			
Obeid 2018										NR/ NR			
Angermann 2019											Ranibizumab or Aflibercept/PRN		

PRN: Pro-re-nata; NR: Not reported; T&E: treat and extend